中晚期肺癌粒子植入联合静脉化疗的临床观察(1)
摘要：目的 观察放射性粒子植入联合静脉化疗治疗中晚期肺癌的疗效及不良反应发生情况。方法 选取2016年3月～2018年1月我科收治的确诊中晚期肺癌患者40例，根据接受治疗方案不同分为两组，研究组20例患者给予放射性粒子植入联合静脉化疗，对照组20例患者给予单纯接受静脉化疗，比较两组患者的治疗有效率和不良反应发生率。结果 两组患者均完成治疗后的随访检查，研究组粒子植入联合静脉化疗后1个月、3个月及6个月的有效率分别为45.00%、45.00%、55.00%，均高于对照组的0、10.00%、20.00%，差異有统计学意义(P<0.05);研究组患者发生气胸3例，出血1例，骨髓抑制患者3例，胃肠道反应7例，脱发1例，其中同时发生骨髓抑制和胃肠道反应1例，同时发生气胸和出血1例，不良反应发生率65.00%;对照组20例患者骨髓抑制患者4例，胃肠道反应8例，脱发2例，其中同时发生骨髓抑制和胃肠道反应1例，同时发生骨髓抑制和脱发1例，发生率60.00%。两组发生率比较差异无统计学意义(P>0.05)。结论 放射性粒子植入联合静脉化疗对于治疗中晚期肺癌近期疗效可靠，相对于单纯化疗，联合治疗并不增加不良反应发生率。
, http://www.100md.com
关键词：放射性粒子;静脉化疗;中晚期肺癌;近期疗效
中图分类号：R734.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.01.030
文章编号：1006-1959(2019)01-0099-04
Clinical Observation of Advanced Lung Cancer Particle Implantation Combined with Intravenous Chemotherapy
WANG Yu，WANG Jiong
(the First Affiliated Hospital of Anhui Medical University，Hefei 230022，Anhui，China)
, 百拇医药
Abstract：Objective To observe the efficacy and adverse reactions of radioactive seed implantation combined with intravenous chemotherapy in the treatment of advanced lung cancer. Methods From March 2016 to January 2018， 40 patients with advanced lung cancer were enrolled in our department. According to the different treatment regimens， 20 patients in the study group were given radioactive particle implantation combined with intravenous chemotherapy. 20 patients in the control group received intravenous chemotherapy alone， and the treatment efficiency and adverse reaction rate were compared between the two groups. Results The follow-up examinations were completed after treatment. The effective rates of 1 month， 3 months and 6 months after the implantation of the patients in the study group were 45.00%， 45.00% and 55.00%， respectively. The scores of the group were 0， 10.00%， 20.00%，the difference was statistically significant (P<0.05). In the study group， there were 3 cases of pneumothorax， 1 case of hemorrhage， 3 cases of myelosuppression， 7 cases of gastrointestinal reaction， and 1 case of hair loss. Among them， 1 case of myelosuppression and gastrointestinal reactions occurred simultaneously， 1 case of pneumothorax and hemorrhage occurred simultaneously， and the incidence of adverse reactions was 65.00%.In the control group， 4 patients had myelosuppression in 20 patients， gastrointestinal reactions in 8 patients， and alopecia in 2 patients， including 1 case of myelosuppression and gastrointestinal reactions， and 1 case of myelosuppression and alopecia， with an incidence of 60.00%. There was no significant difference in the incidence between the two groups (P>0.05). Conclusion Radioactive seed implantation combined with intravenous chemotherapy is a reliable method for the treatment of advanced lung cancer. Compared with chemotherapy alone， combination therapy does not increase the incidence of adverse reactions., 百拇医药(王宇 王炯)
, http://www.100md.com
关键词：放射性粒子;静脉化疗;中晚期肺癌;近期疗效
中图分类号：R734.2 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.01.030
文章编号：1006-1959(2019)01-0099-04
Clinical Observation of Advanced Lung Cancer Particle Implantation Combined with Intravenous Chemotherapy
WANG Yu，WANG Jiong
(the First Affiliated Hospital of Anhui Medical University，Hefei 230022，Anhui，China)
, 百拇医药
Abstract：Objective To observe the efficacy and adverse reactions of radioactive seed implantation combined with intravenous chemotherapy in the treatment of advanced lung cancer. Methods From March 2016 to January 2018， 40 patients with advanced lung cancer were enrolled in our department. According to the different treatment regimens， 20 patients in the study group were given radioactive particle implantation combined with intravenous chemotherapy. 20 patients in the control group received intravenous chemotherapy alone， and the treatment efficiency and adverse reaction rate were compared between the two groups. Results The follow-up examinations were completed after treatment. The effective rates of 1 month， 3 months and 6 months after the implantation of the patients in the study group were 45.00%， 45.00% and 55.00%， respectively. The scores of the group were 0， 10.00%， 20.00%，the difference was statistically significant (P<0.05). In the study group， there were 3 cases of pneumothorax， 1 case of hemorrhage， 3 cases of myelosuppression， 7 cases of gastrointestinal reaction， and 1 case of hair loss. Among them， 1 case of myelosuppression and gastrointestinal reactions occurred simultaneously， 1 case of pneumothorax and hemorrhage occurred simultaneously， and the incidence of adverse reactions was 65.00%.In the control group， 4 patients had myelosuppression in 20 patients， gastrointestinal reactions in 8 patients， and alopecia in 2 patients， including 1 case of myelosuppression and gastrointestinal reactions， and 1 case of myelosuppression and alopecia， with an incidence of 60.00%. There was no significant difference in the incidence between the two groups (P>0.05). Conclusion Radioactive seed implantation combined with intravenous chemotherapy is a reliable method for the treatment of advanced lung cancer. Compared with chemotherapy alone， combination therapy does not increase the incidence of adverse reactions., 百拇医药(王宇 王炯)